Group 1 - The core viewpoint of the article highlights the financial performance and market position of Aier Eye Hospital Group, indicating a decline in stock price and its relative valuation within the medical services industry [1] - As of May 15, Aier Eye Hospital's stock closed at 12.87 yuan, down 1.91%, with a rolling PE ratio of 32.39 times and a total market capitalization of 1200.39 billion yuan [1] - The average PE ratio for the medical services industry is 37.79 times, with a median of 38.85 times, placing Aier Eye Hospital at the 25th position in the industry ranking [1] Group 2 - As of the first quarter of 2025, 107 institutions hold shares in Aier Eye Hospital, including 105 funds, with a total shareholding of 416,294.56 million shares valued at 552.84 billion yuan [1] - The company's main business includes diagnosis and surgical services for various eye diseases, with key products being refractive projects, cataract projects, anterior segment projects, posterior segment projects, and optometry services [1] - The latest financial results for the first quarter of 2025 show that the company achieved a revenue of 60.26 billion yuan, a year-on-year increase of 15.97%, and a net profit of 10.50 billion yuan, up 16.71%, with a gross profit margin of 48.02% [1]

Group 1: 华峰化学 - Company decided to terminate the acquisition of 100% equity in Zhejiang Huafeng Synthetic Resin Co., Ltd. and Zhejiang Huafeng Thermoplastic Polyurethane Co., Ltd. due to insufficient shareholder approval [1] - The decision was made based on prudence, as the proposal did not receive more than two-thirds of the valid voting rights at the shareholders' meeting [1] - Company will continue to promote related equity injection work and strictly fulfill asset injection commitments [1] Group 2: 中荣股份 - Actual controller and chairman Huang Huanran has been placed under residential surveillance by the police [2] - Other board members and senior management are performing their duties normally, and the board of directors is operating as usual [2] - Company specializes in the research, design, production, and sales of paper printing and packaging products [2] Group 3: 密尔克卫 - Three shareholders plan to reduce their holdings by a total of up to 2% of the company's shares through block trading [3] - The reduction includes 143.63 million shares, 97.65 million shares, and 75.03 million shares, representing 0.91%, 0.62%, and 0.47% of the total share capital respectively [3] - The reduction period is from June 6, 2025, to September 5, 2025, due to personal funding needs [3] Group 4: 舒泰神 - Subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. has obtained a drug production license from the Jiangsu Provincial Drug Administration [4] - The license allows for the production of therapeutic biological products, specifically for registered declaration use [4] - The license is valid until May 7, 2030, and is not expected to have a significant impact on the company's current performance [4] Group 5: 捷顺科技 - Company won the bid for the "Chongqing Beautiful Sunshine Home and other public rental housing supporting parking space operation project" [5] - The project includes four public rental housing supporting parking lots with a total of 13,335 parking spaces [5] - The minimum guaranteed revenue for the project is quoted at 40.43 million yuan per year, with a total contract amount expected to exceed 100 million yuan [5] Group 6: 综艺股份 - Company signed an investment cooperation intention agreement to acquire control of Jiangsu Jilai Microelectronics Co., Ltd. through cash capital increase or share transfer [6] - Jilai Micro primarily engages in the research, production, and sales of power semiconductor chips and devices [6] - The transaction is expected to constitute a major asset restructuring [6] Group 7: 东山精密 - Subsidiary DSBJ PTE. LTD. plans to acquire 100% equity of French GMD Group for approximately 100 million euros (about 814 million yuan) [7] - The acquisition aims to advance the company's globalization strategy and enhance its market share in the automotive parts sector [7] - The company specializes in the research, production, and sales of electronic circuit products and precision components [7] Group 8: 诺诚健华 - Company reported a net profit of 17.97 million yuan for the first quarter of 2025, a significant turnaround from a loss of 142 million yuan in the same period last year [8] - The first quarter revenue reached 381 million yuan, representing a year-on-year growth of 129.92% [8] - The company focuses on the research, production, and commercialization of innovative drugs [8] Group 9: 凯美特气 - Shareholders plan to reduce their holdings by up to 3% of the company's shares through centralized bidding and/or block trading [9] - The total number of shares to be reduced is 20.86 million [9] - The reduction is due to personal funding needs [9] Group 10: 海创药业 - Controlling shareholder plans to reduce holdings by up to 2% of the company's shares through centralized bidding and block trading [10] - The total number of shares to be reduced is 1.98 million [10] - The reduction is due to personal funding needs [10] Group 11: 高争民爆 - Controlling shareholder plans to reduce holdings by up to 3% of the company's shares through centralized bidding and block trading [11] - The total number of shares to be reduced is 828,000 [11] - The reduction is due to the company's funding needs [11] Group 12: 金埔园林 - Two shareholders plan to reduce their holdings by a total of up to 1.91% of the company's shares [12] - The reductions include 183.93 million shares and 167.73 million shares [12] - The reasons for the reductions are asset optimization and personal funding needs [12] Group 13: 掌趣科技 - The largest shareholder plans to reduce holdings by up to 1% of the company's shares through centralized bidding or block trading [13] - The total number of shares to be reduced is 27.2 million [13] - The reduction is due to personal funding needs [13] Group 14: 美凯龙 - Company announced that its director and general manager has been placed under investigation and detention by the local supervisory committee [14] - Other board members and senior management are performing their duties normally, and daily operations are unaffected [14] - The company specializes in managing and operating self-operated and franchised shopping malls [14] Group 15: 新强联 - Major shareholder plans to reduce holdings by up to 1.89% of the company's shares through centralized bidding and block trading [15] - The total number of shares to be reduced is 717,490 [15] - The reduction is due to operational needs [15] Group 16: 日月明 - Shareholder plans to reduce holdings by up to 1% of the company's shares through centralized bidding [16] - The total number of shares to be reduced is 80,000 [16] - The reduction is due to personal funding needs [16] Group 17: 同有科技 - Major shareholder and vice president plan to reduce their holdings by up to 1.53% of the company's shares [17] - The total number of shares to be reduced is 730,850 [17] - The reduction is due to personal funding needs [17] Group 18: 爱尔眼科 - Subsidiary successfully acquired 60% equity and specific debt of Shenzhen Guangsheng Digital Technology Co., Ltd. for 650 million yuan [18] - The transaction constitutes a related party transaction [18] - The acquired asset will serve as long-term medical premises for the subsidiary [18]

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-039 爱尔眼科医院集团股份有限公司 关于公开摘牌取得深圳广晟数码技术有限公司 60%股权 及特定债权暨关联交易的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、交易内容：爱尔眼科医院集团股份有限公司（以下简称"公司"）的全资子公司深 圳滨海爱尔眼科医院（以下简称"深圳滨海爱尔"）通过广东联合产权交易中心公开摘牌获得 深圳广晟数码技术有限公司 60%股权及特定债权项目，本次交易以自有资金支付，交易价 格为人民币 64,961.478241 万元。标的公司的资产包括"广晟科创大厦"，将作为深圳滨海爱 尔的长期医疗用房。 2、本次交易构成关联交易。 鉴于本次交易存在不确定性且涉及公司商业秘密，若在摘牌完成前披露该事 项，可能误导投资者，亦可能导致标的价格提高从而损害公司和股东利益。根据 《深圳证券交易所创业板股票上市规则》及公司《信息披露暂缓与豁免制度》的 相关规定，公司审慎判断，于 2025 年 4 月 16 日召开第六届董事会第三十三次会 议审议通过《关于全资子公司深圳滨海爱尔 ...

Core Viewpoint - The recent policy announced by Trump to align U.S. drug prices with the lowest global prices could lead to a significant decrease in prescription drug prices in the U.S., potentially by 30% to 80%, raising concerns among pharmaceutical companies, especially those exporting to the U.S. [1][2] Group 1: Market Performance - As of May 13, 2025, the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index (930965) rose by 2.42%, with notable increases in stocks such as BeiGene (06160) up 4.15% and Innovent Biologics (01801) up 3.14% [1] - The Hong Kong Pharmaceutical ETF (159718) opened high and increased by 2.04%, with a latest price of 0.70 yuan, and a one-month cumulative increase of 3.32% [1] - The CSI Pharmaceutical and Medical Device Innovation Index (931484) increased by 0.87%, with stocks like East China Pharmaceutical (000963) rising by 2.23% [4] Group 2: Trading Volume and Liquidity - The Hong Kong Pharmaceutical ETF had a turnover of 1.72% during the trading session, with a transaction volume of 4.0999 million yuan, and an average daily transaction volume of 95.7602 million yuan over the past month [1] - The latest scale of the Medical Innovation ETF (516820) reached 1.588 billion yuan [4] Group 3: Index Composition - The top ten weighted stocks in the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index accounted for 60.54% of the index, including BeiGene (06160) and WuXi Biologics (02269) [5] - The top ten weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index represented 66.51% of the index, featuring companies like Hengrui Medicine (600276) and WuXi AppTec (603259) [8]

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential for future growth [20]. 4. Blood Products - The report highlights the strong pricing power of manufacturers in the blood products sector, driven by increased demand for immunoglobulin products [22]. 5. Vaccine Sector - The vaccine sector is facing challenges due to low birth rates, but there are opportunities in specific areas such as HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD sector is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drugs [37]. 9. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [42]. 10. Offline Pharmacies - The report indicates that leading pharmacy chains are stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. 11. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [51]. 13. Instrument Equipment - The report notes that the scientific instrument sector is expected to recover as demand improves and more domestic support policies are introduced [56]. 14. Low-value Consumables - The report suggests that the low-value consumables sector may see investment opportunities as the industry cycle improves [59].

Core Viewpoint - The introduction of the minimally invasive all-laser precise 4.0-VISULYZE technology by Suqian Aier Eye Hospital marks a significant advancement in the refractive surgery field, responding to the increasing demand for safety, precision, and personalization in myopia correction surgeries [1][13]. Group 1: Technological Advancements - The development of refractive surgery has reached multiple milestones, with the introduction of the all-laser SMILE technology representing the 3.0 era, and the new 4.0-VISULYZE technology being a comprehensive upgrade focused on intelligent and personalized care [1][4]. - The 4.0-VISULYZE technology features four core innovations: visualized surgical results, full-process variable control, personalized Nomogram analysis system, and a closed-loop patient management system, ensuring precise control throughout the surgical process [4][6]. Group 2: Precision and Safety Enhancements - The technology utilizes big data algorithms to analyze various patient-specific metrics, allowing for customized surgical plans that move away from traditional one-size-fits-all approaches [6]. - Full environmental, process, and variable management significantly reduces postoperative refractive errors and lowers the risk of complications such as dry eyes and glare, providing a more stable and safer postoperative experience [8]. - Compared to traditional laser and semi-laser technologies, the 4.0 technology reduces the corneal cutting area by approximately 45%, preserving corneal nerve integrity and enhancing postoperative visual quality, leading to quicker recovery and a more comfortable visual experience [11].

Core Viewpoint - The ChiNext 50 Index has shown strong performance, with significant gains in constituent stocks, indicating a favorable environment for technology growth and investment opportunities in the ChiNext market [1][2]. Group 1: Index Performance - As of May 12, 2025, the ChiNext 50 Index (399673) rose by 2.34%, with stocks like AVIC Chengfei (302132) hitting a 20% limit up and currently up by 17.80% [1]. - The ChiNext 50 ETF (159681) increased by 2.06%, with the latest price at 0.89 yuan [1]. - The latest scale of the ChiNext 50 ETF reached 1.531 billion yuan, ranking it among the top comparable funds [1]. Group 2: Fund Growth and Fees - The ChiNext 50 ETF has seen a significant increase in shares, with a growth of 216 million shares over the past six months, placing it at the top among comparable funds [1]. - The management fee for the ChiNext 50 ETF is 0.15%, and the custody fee is 0.05%, making it the lowest in its category [1]. Group 3: Market Sentiment and Valuation - According to Kaiyuan Securities, the technology growth style is worth focusing on, with a resurgence in mergers and acquisitions and continued domestic policy support for the technology sector [1]. - Guotai Junan Securities suggests that the risk premium in the Chinese stock market is likely to decrease systematically, with the ChiNext 50 Index's price-to-book ratio (PB) at 4.56 times, significantly lower than 84.1% of the time over the past five years, indicating strong valuation attractiveness [1][2]. Group 4: Composition of the Index - The ChiNext 50 Index consists of 50 stocks with high average daily trading volumes, primarily representing well-known, large-cap, and liquid companies in the ChiNext market [2]. - As of April 30, 2025, the top ten weighted stocks in the ChiNext 50 Index accounted for 64.53% of the index, including companies like Ningde Times (300750) and Mindray Medical (300760) [2].

Investment Rating - The investment rating for Aier Eye Hospital Group is Underweight [5][68]. Core Views - The industry view is considered Attractive, indicating a positive outlook for the sector [5][68]. - Aier Eye Hospital Group has experienced solid year-to-date growth in the refractory segment, with over 20% growth driven by improved average selling prices (ASP) and volume [3][8]. - The company plans to upgrade more SMILE 4.0 and Wavelight Plus equipment and launch ICL V5 to enhance its technology lead and drive ASP growth [3][8]. Summary by Sections Refractory Segment - The refractory segment has shown significant growth, with a 20%+ increase in 1Q25, attributed to ASP improvements and a recovery in end-demand [3][8]. - ICL procedures have also reversed the declining trend seen in 2024, contributing positively to year-over-year growth [3]. Cataract Segment - The cataract segment experienced single-digit percentage growth in 1Q25, with volume growth higher year-over-year, although blended prices continued to decline due to value-based pricing (VBP) expansion for intraocular lenses (IOLs) [4][8]. - Multi-focal lenses, which are fully paid out-of-pocket, have shown faster year-over-year growth compared to bifocal lenses, which are under VBP [4]. Financial Metrics - For the fiscal year ending December 2025, the estimated revenue is Rmb22,963 million, with an EPS of Rmb0.45 [5]. - The company is projected to have a P/E ratio of 29.1 and a return on equity (ROE) of 20.2% for the same period [5]. Market Performance - The current market capitalization of Aier Eye Hospital Group is Rmb122,575 million, with an average daily trading value of Rmb1,168 million [5]. - The stock price as of May 7, 2025, is Rmb13.14, with a price target set at Rmb11.50, indicating a potential downside of 12% [5].

Summary of the Conference Call Industry Focus - The report focuses on the pharmaceutical industry, specifically highlighting innovative drugs and contract research organizations (CXO) Core Insights and Arguments - Continuous recommendation of innovative drugs with positive growth outlook, including: - 恒瑞医药 (Hengrui Medicine) - 华东医药 (East China Pharmaceutical) - 翰森制药 (Hansoh Pharmaceutical) - 贝达药业 (Betta Pharmaceuticals) - 信立泰 (Sinopharm) - 科伦药业 (Kelun Pharmaceutical) - 百利天恒 (Baili Tianheng) - 荣昌生物 (Rongchang Biopharmaceutical) - 科伦博泰生物 (Kelun Biotech) - 石药集团 (Shijiazhuang Pharmaceutical Group) [1][1][1] - Recommendation of CXOs showing signs of profit growth turning points, including: - 药明生物 (WuXi Biologics) - 药明康德 (WuXi AppTec) [1][1] - Positive outlook on domestic replacement of innovative medical devices, specifically: - 惠泰医疗 (Huitai Medical) [1] - Anticipation of recovery in consumer healthcare, particularly: - 爱尔眼科 (Aier Eye Hospital) [1] Other Important Points - The report emphasizes the ongoing trend of recommending companies that are positioned well within the pharmaceutical sector, particularly those that are expected to benefit from market dynamics and growth opportunities - The focus on innovative drugs and CXOs indicates a strategic approach to capitalize on emerging trends in the healthcare market - The mention of domestic replacements in medical devices suggests a shift towards local production and innovation, which could impact market competition and supply chains - The recovery in consumer healthcare points to potential growth areas as the market stabilizes post-pandemic

华泰联合证券有限责任公司 关于爱尔眼科医院集团股份有限公司 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 二、保荐机构基本情况 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 华泰联合证券有限责任公司 | | 注册地址 | 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金 | | | 小镇 B7 栋 401 | | 主要办公地址 | 北京市西城区丰盛胡同 22 号丰铭国际大厦 A 座 6 层 | | 法定代表人 | 江禹 | | 联系人 | 丁明明、高元 | | 联系电话 | 010-56839300 | 1 三、发行人基本情况 向特定对象发行股票 之保荐总结报告书 | 保荐机构名称 | 华泰联合证券有限责任公司 | | --- | --- | | 保荐机构编号 | Z26774000 | 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下 ...